Taiho Oncology, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 1 with a minor change only.

1. Notable

   REZILIENT4 · Zipalertinib Versus Placebo · Early Stage NSCLC…REZILIENT4 · Zipalertinib Versus Placebo · Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

   Enrollment reopened

   Taiho Oncology, Inc.·Phase 3· NCT07128199· Registry history of NCT07128199 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.